Feature TransEnterix readying FDA filing of SurgiBot in mid-year By Len Zehr TransEnterix (NYSE MKT:TRXC) plans to file for FDA approval in mid-year of its SurgiBot robotic platform to enhance minimally invasive laparoscopic surgery through a single surgical incision. “We anticipate... April 28, 2015